Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Vaccine

• Publication date

  2011-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2011.09.049PMID 21945964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-based design of NS2 mutants for attenuated influenza A virus vaccines.

  2011cited by this paper
• Comparison of a live attenuated 2009 H1N1 vaccine with seasonal influenza vaccines against 2009 pandemic H1N1 virus infection in mice and ferrets.

  2011cited by this paper
• WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer.

  2011cited by this paper
• Efficacy of Vaccination with Different Combinations of MF59-Adjuvanted and Nonadjuvanted Seasonal and Pandemic Influenza Vaccines against Pandemic H1N1 (2009) Influenza Virus Infection in Ferrets

  2011cited by this paper
• Severity of Pneumonia Due to New H1N1 Influenza Virus in Ferrets Is Intermediate between That Due to Seasonal H1N1 Virus and Highly Pathogenic Avian Influenza H5N1 Virus

  2010cited by this paper
• The 2009 A (H1N1) influenza virus pandemic: A review.

  2010cited by this paper
• NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets.

  2010cited by this paper
• Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus

  2010cited by this paper
• In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses

  2009cited by this paper
• Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children

  2009cited by this paper
• Influenza A Virus Lacking M2 Protein as a Live Attenuated Vaccine

  2009cited by this paper
• Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

  2009cited by this paper
• Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings

  2009cited by this paper
• Phenotypic characteristics of novel swine‐origin influenza A/California/07/2009 (H1N1) virus

  2009cited by this paper
• Generation of Live Attenuated Novel Influenza Virus A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs

  2009cited by this paper
• Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009.

  2009cited by this paper
• Attenuated influenza virus vaccines with modified NS1 proteins.

  2009cited by this paper
• Pandemic (H1N1) 2009 influenza ("swine flu") in Australian and New Zealand intensive care.

  2009cited by this paper
• Seasonal Influenza Vaccine Provides Priming for A/H1N1 Immunization

  2009cited by this paper
• Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine.

  2009cited by this paper
• Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I–II clinical trials)

  2008cited by this paper
• Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.

  2005cited by this paper
• Cold-adapted, live attenuated influenza vaccine

  2004cited by this paper
• Demystifying FluMist, a new intranasal, live influenza vaccine.

  2003cited by this paper
• Principles Underlying the Development and Use of Live Attenuated Cold-Adapted Influenza A and B Virus Vaccines

  2002cited by this paper
• Preparation and characterisation of attenuated cold-adapted influenza A reassortants derived from the A/Leningrad/134/17/57 donor strain.

  2002cited by this paper
• Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults.

  2001cited by this paper
• Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents.

  2000cited by this paper
• The development of live attenuated cold‐adapted influenza virus vaccine for humans

  1999cited by this paper
• Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds.

  1996cited by this paper
• Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine

  1995cited by this paper
• Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia.

  1993cited by this paper

• Differential patterns of cross-protection against antigenically distinct variants in small animal models of SARS-CoV-2 infection

  2024cites this paper
• Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity

  2020cites this paper
• Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.

  2018cites this paper
• Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains

  2017cites this paper
• MOUSE MODEL FOR THE STUDY OF ATTENUATION OF COLD-ADAPTED INFLUENZA VIRUSES

  2017cites this paper
• Evaluation of a candidate live attenuated influenza vaccine prepared in Changchun BCHT (China) for safety and efficacy in ferrets.

  2016cites this paper
• Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories

  2016cites this paper
• Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus

  2015cites this paper
• Safety, immunogenicity and infectivity of new live attenuated influenza vaccines

  2015cites this paper
• Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge

  2014cites this paper
• Intranasally administered Endocine formulated 2009 pandemic influenza H1N1 vaccine induces broad specific antibody responses and confers protection in ferrets.

  2014cites this paper
• Effectiveness of an Indian-made Attenuated influenza A(H1N1)pdm 2009 vaccine

  2014cites this paper
• Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices.

  2014cites this paper
• Characterizing immunogenetic factors associated with influenza cross-reactive responses and disease severity

  2014influential citation
• Understanding key parameters affecting needle-free skin penetration by a parenteral drug delivery system

  2013cites this paper
• The Estonian H1N1 influenza 2009 outbreak was highly underestimated

  2012cites this paper
• Consecutive CT in vivo lung imaging as quantitative parameter of influenza vaccine efficacy in the ferret model.

  2012cites this paper